1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Abbott Laboratories

Abbott Laboratories

ABL.DE
Abbott LaboratoriesDE flagDeutsche Börse
84.38
EUR
+1.60
- -
146.97BMarket Cap
Abbott Laboratories
ABL.DE
(Deutsche Börse)

Recent

price

84.38

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
22.73
13.63
12.08
12.7
13.43
13.86
14.16
15.71
17.42
18.1
19.54
24.42
25.12
23.13
24.22
25.53
25.94
Revenue per Share
2.99
3.01
3.78
1.66
1.51
3
0.95
0.27
1.35
2.09
2.54
4.01
3.99
3.3
7.74
3.76
3.61
Basic EPS, GAAP
4.99
4.76
4.77
1.41
1.72
1.26
1.41
2.54
2.79
2.55
3.23
4.9
4.49
2.92
3.67
4.26
4.24
Free Cash Flow per Basic Share
1.73
1.87
2.02
0.57
0.89
0.98
1.04
1.06
1.12
1.29
1.45
1.82
1.9
2.05
2.22
2.37
2.41
Dividend per Share
18.07
19.57
22.77
21.98
23.38
26.14
26.2
27.06
27.38
28.2
29.23
31.74
34.51
36
41.82
43.37
43.29
Book Value per Share
-3.44
-0.74
1.55
6.3
3.56
4.16
5.77
-8.26
-6.54
-5.06
-3.12
0.03
2.1
3.65
10.48
13.37
-0.23
Tangible Book Value per Share
1,547
1,570
1,577
1,548
1,508
1,473
1,473
1,744
1,756
1,763
1,771
1,764
1,738
1,734
1,732
1,737
1,740
Basic Weighted Avg Shares
35,167
21,407
19,050
19,657
20,247
20,405
20,853
27,390
30,578
31,904
34,608
43,075
43,653
40,109
41,950
44,328
45,134
Sales/Revenue/Turnover
18.2
7.61
7.14
10.85
12.84
14.05
14.51
5.71
11.94
14.21
15.48
19.56
19.16
16.15
16.27
18.17
17.07
Operating Margin (%)
2,624
3,044
2,782
1,719
1,548
1,472
1,353
3,021
3,278
3,014
3,327
3,538
3,267
3,243
3,218
3,116
3,163
Depreciation Expense
4,626
4,728
5,963
2,576
2,284
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
5,723
13,402
6,524
6,276
Net Income, GAAP
19.02
8.9
- -
2.6
31.65
18.13
24.77
84.18
18.76
9.57
10
13.88
16.53
14.12
- -
22.94
22.87
Effective Tax Rate (%)
13.15
22.09
31.3
13.1
11.28
21.68
6.71
1.74
7.74
11.56
12.99
16.42
15.88
14.27
31.95
14.72
13.91
Profit Margin (%)
5,055
8,289
18,043
9,740
3,089
4,969
20,116
11,235
5,620
4,804
8,534
11,134
9,735
8,829
9,499
9,500
7,131
Working Capital
12,524
12,040
18,085
3,388
3,393
5,871
20,681
27,210
19,359
17,416
19,429
18,252
15,465
14,548
13,521
10,827
29,638
LT Debt
22,765
24,526
26,813
25,267
21,639
21,326
20,717
31,098
30,722
31,301
33,003
36,024
36,905
38,827
47,901
52,771
52,701
Total Equity
12.58
3.59
- -
5.24
5.81
7.84
6.23
0.49
5.43
8.17
9.4
13.51
12.77
10.21
- -
9.56
7.97
Return on Invested Capital (%)
12.6
10.85
- -
5.59
5.69
10.04
3.18
0.91
4.25
6.28
7.1
10.25
9.66
8.03
- -
7.78
6.81
Return on Capital (%)
20.55
16.11
17.9
7.37
6.59
11.99
3.63
1.11
4.97
7.54
8.86
13.12
11.96
9.35
19.88
8.83
8.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,345
3,033
4,409
LT Borrowings
11,596
9,896
29,638
LT Finance Leases
- -
931
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,739
1,737
1,742
Market Capitalization
231,466
216,362
177,427

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
24,839
25,996
25,508
Cash, Cash Equivalents & STI
7,733
8,939
7,295
Accounts Receivable, Net
8,138
7,929
8,210
Inventories
6,708
6,488
6,989
Total Current Liabilities
14,582
16,496
18,377
Payables & Accruals
13,237
13,463
13,968
ST Debt
1,345
3,033
4,409
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.37%
10.07%
10.17%
Free Cash Flow
20.29%
9.63%
16.44%
Net Income, GAAP
46.05%
24.15%
-51.32%
Sales/Revenue/Turnover
8.6%
5.59%
5.67%
Total Cash Common Dividend
11.24%
10.21%
7.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,964
10,377
10,635
10,974
41,950
2025
10,358
11,142
11,369
11,459
44,328
2026
11,164
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
0.75
0.95
5.33
7.74
2025
0.76
1.02
- -
1.02
3.76
2026
0.62
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.55
0.55
0.55
2.22
2025
0.59
0.59
- -
0.59
2.37
2026
0.63
- -
- -
- -
- -
Similar Companies
Aquarius Surgical Technologies Inc. (AQQRF)
HOB Biotech Group Corp.,Ltd (688656.SS)
Hancock Jaffe Laboratories, Inc. Warrants (HJLIW)
Zecotek Photonics Inc. (ZMSPF)
Medacta Group S.A. (MEDGF)
TransMedics Group, Inc. (TMDX)
Business
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad portfolio of health care products operating globally across four main segments: medical devices, diagnostics, nutrition, and established pharmaceuticals. The company's core products include medical devices such as cardiovascular devices, glucose monitoring systems under the FreeStyle Libre brand, neuromodulation devices for chronic pain and movement disorders, diagnostic tools including point-of-care testing and laboratory diagnostics, and nutrition products including infant formula and adult nutritionals. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott has expanded its portfolio through strategic acquisitions including the 2025 acquisition of Exact Sciences, enhancing its position in cancer screening and precision oncology diagnostics. Recent operational initiatives include the FDA approval of the Tendyne transcatheter mitral valve replacement system and plans to establish a new cardiovascular device manufacturing facility in Georgia by 2028. Abbott continues to drive organic growth through innovation in its diversified portfolio, with medical devices leading quarterly sales performance, and maintains a strong presence in the U.S. cardiovascular market with significant market share. The company’s recent acquisitions such as Bigfoot Biomedical, Cardiovascular Systems, and Exact Sciences reflect a strategic emphasis on expanding diabetes management, cardiovascular treatments, and oncology diagnostics globally, supporting its long-term growth strategy and global commercial reach. Abbott serves diverse healthcare markets worldwide including North America, Europe, Asia, and emerging markets. Its extensive network includes over 300 subsidiaries that support its innovation and distribution capabilities. Abbott continually invests in research and development to improve patient outcomes and address global health challenges.